
The present invention provides a pharmaceutical composition, primarily for the treatment of inflammatory conditions, including benign prostata hypertrophy, the composition containing a spiroketalin such as diosgenyl-.beta.-D-glycoside or hecogenyl-.beta.-D-glycoside. A unit dosage form is provided which contains between 0,3 and 0,75 mgm of the spiroketalin.










